# SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)

> **NCT00783393** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 32 (actual)

## Conditions studied

- Astrocytoma

## Interventions

- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00783393
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05-27
- **Primary completion:** 2005-06-17
- **Final completion:** 2005-06-17
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00783393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00783393, "SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00783393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*